Immatics (IMTX) Capital Expenditures (2019 - 2025)
Immatics (IMTX) posted Capital Expenditures of -$1.1 million for Q4 2025, up 10.98% sequentially from -$1.3 million in Q3 2025, and up 36.88% YoY from -$824903.9 in Q4 2024.
Immatics (IMTX) Capital Expenditures (2019 - 2025) Analysis & Trends
Immatics has reported Capital Expenditures for 7 years, with the latest figure at -$1.1 million in Q4 2025.
- Quarterly Capital Expenditures rose 36.88% year-over-year to -$1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.2 million (up 58.95% YoY) and the FY2025 annual result came in at -$7.4 million, up 57.93% from the prior year.
- Capital Expenditures improved to -$1.1 million in Q4 2025 per IMTX's latest filing, from -$1.3 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $56.3 million in Q4 2023 and troughed at -$11.6 million in Q2 2023.
- A 5-year average of $386663.4 and a median of -$1.6 million in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures soared 545.09% in 2022, then slumped 1248.09% in 2023.
- Over 5 years, Capital Expenditures stood at -$2.1 million in 2021, then jumped by 545.09% to $9.3 million in 2022, then surged by 504.3% to $56.3 million in 2023, then slumped by 103.18% to -$1.8 million in 2024, then soared by 36.88% to -$1.1 million in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$1.1 million, -$1.3 million, and -$1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | -1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.13 Mn |
| Dec 31, 2025 | -1.13 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Jun 30, 2025 | -1.62 Mn |
| Jun 30, 2025 | -1.62 Mn |
| Mar 31, 2025 | -3.23 Mn |
| Mar 31, 2025 | -3.23 Mn |
| Dec 31, 2024 | -1.79 Mn |
| Dec 31, 2024 | -1.79 Mn |
| Sep 30, 2024 | -3.08 Mn |
| Sep 30, 2024 | -3.08 Mn |
| Jun 30, 2024 | -2.82 Mn |
| Jun 30, 2024 | -2.82 Mn |
| Mar 31, 2024 | -9.97 Mn |
| Mar 31, 2024 | -9.97 Mn |
| Dec 31, 2023 | 56.28 Mn |
| Dec 31, 2023 | 56.28 Mn |
| Sep 30, 2023 | -7.08 Mn |
| Sep 30, 2023 | -7.08 Mn |